Generics Bulletin

Hyloris Closes A Dramatic 2024 With A Move Towards Profit

The Firm Reported Increased Revenue Driven By Royalties

25 Mar 2025

After announcing updates in its ongoing legal battle and a leadership shakeup earlier this fiscal year, Hyloris closed 2024 with a slight rise in revenue and a shrinking of its reported net loss.

Belgium map and flag — Belgium updates rules on importing unlicensed products

Hyloris Pharmaceuticals has reported a slight rise in its total revenue as part of its full year results for 2024, marking a close to a particularly tumultuous period for the Belgian value-added medicines specialist that has moved closer to profit.

For the whole of the 2024 financial year, Hyloris reported growth in its total revenue and other operating income to...